Related references
Note: Only part of the references are listed.Novel Risk Score Efficiently Prevents Tolvaptan-Induced Hypernatremic Events in Patients With Heart Failure
Koichiro Kinugawa et al.
CIRCULATION JOURNAL (2018)
The Effect of Door-to-Diuretic Time on Clinical Outcomes in Patients With Acute Heart Failure
Jin Joo Park et al.
JACC-HEART FAILURE (2018)
Impaired Myocardial Sympathetic Innervation Is Associated with Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction: 11C-Hydroxyephedrine PET Study
Tadao Aikawa et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure
Yuya Matsue et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decornpensated Heart Failure and Preserved Left Ventricular Ejection Fraction - Prospective Randomized Controlled Study -
Shunsuke Tamaki et al.
CIRCULATION JOURNAL (2017)
Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2-and 5-year risk models
Kenichi Nakajima et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2016)
Abnormal adrenergic activation is the major determinant of reduced functional capacity in heart failure with preserved ejection fraction
L. R. Messias et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial
Andrew P. Ambrosy et al.
EUROPEAN HEART JOURNAL (2013)
Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure with Preserved Ejection Fraction
Shunsuke Tamaki et al.
PLOS ONE (2013)
Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction Prevalence, Therapies, and Outcomes
Benjamin A. Steinberg et al.
CIRCULATION (2012)
Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions
Berlinda J. van der Veen et al.
JOURNAL OF NUCLEAR CARDIOLOGY (2012)
Efficacy and Safety of Tolvaptan in Heart Failure Patients with Sustained Volume Overload despite the Use of Conventional Diuretics: A Phase III Open-Label Study
Masatake Fukunami et al.
CARDIOVASCULAR DRUGS AND THERAPY (2011)
Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction
Shigehiko Katoh et al.
ANNALS OF NUCLEAR MEDICINE (2010)
Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure Results of the Prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study
Arnold F. Jacobson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Impact of Intravenous Loop Diuretics on Outcomes of Patients Hospitalized with Acute Decompensated Heart Failure: Insights from the ADHERE Registry
W. Franklin Peacock et al.
CARDIOLOGY (2009)
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
LC Costello-Boerrigter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Acute heart failure syndromes -: Current state and framework for future research
M Gheorghiade et al.
CIRCULATION (2005)
Share Paper
